EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 39 / Numéro 2 (Février 2023) Med Sci (Paris), 39 2 (2023) 101-104 Références
Open Access
Numéro
Med Sci (Paris)
Volume 39, Numéro 2, Février 2023
Page(s) 101 - 104
Section Nouvelles
DOI https://doi.org/10.1051/medsci/2023001
Publié en ligne 17 février 2023
  1. Okazaki T, Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int Immunol 2007 ; 19 : 813–824. [CrossRef] [PubMed] [Google Scholar]
  2. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov 2018 ; 8 : 1069–1086. [CrossRef] [PubMed] [Google Scholar]
  3. Sharma P, Allison JP. Dissecting the mechanisms of immune checkpoint therapy. Nat Rev Immunol 2020; 20 : 75–6. [CrossRef] [PubMed] [Google Scholar]
  4. Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol 2016 ; 13 : 473–486. [Google Scholar]
  5. Johnson DB, Nebhan CA, Moslehi JJ, et al. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol 2022; 19 : 254–67. [CrossRef] [PubMed] [Google Scholar]
  6. Ramos-Casals M, Brahmer JR, Callahan MK, et al. Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers 2020; 6 : 38. [CrossRef] [PubMed] [Google Scholar]
  7. Meylan M, Petitprez F, Becht E, et al. Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer. Immunity 2022; 55 : 527–41.e5. [CrossRef] [PubMed] [Google Scholar]
  8. Mazor RD, Nathan N, Gilboa A, et al. Tumor-reactive antibodies evolve from non-binding and autoreactive precursors. Cell 2022; 185 : 1208–22.e21. [CrossRef] [PubMed] [Google Scholar]
  9. Shahabi V, Berman D, Chasalow SD, et al. Gene expression profiling of whole blood in ipilimumab-treated patients for identification of potential biomarkers of immune-related gastrointestinal adverse events. J Transl Med 2013 ; 11 : 75. [CrossRef] [PubMed] [Google Scholar]
  10. Barr TA, Shen P, Brown S, et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6–producing B cells. J Exp Med 2012 ; 209 : 1001–1010. [CrossRef] [PubMed] [Google Scholar]
  11. Li R, Rezk A, Miyazaki Y, et al. Proinflammatory GM-CSF–producing B cells in multiple sclerosis and B cell depletion therapy. Sci Transl Med 2015; 7 : 310ra166–310ra166. [PubMed] [Google Scholar]
  12. Oleinika K, Mauri C, Salama AD. Effector and regulatory B cells in immune-mediated kidney disease. Nat Rev Nephrol 2019 ; 15 : 11–26. [CrossRef] [PubMed] [Google Scholar]
  13. Catalán D, Mansilla MA, Ferrier A, et al. Immunosuppressive mechanisms of regulatory B cells. Front Immunol 2021; 12 : 611795. [CrossRef] [PubMed] [Google Scholar]
  14. Fridman WH, Meylan M, Petitprez F, et al. B cells and tertiary lymphoid structures as determinants of tumour immune contexture and clinical outcome. Nat Rev Clin Oncol 2022; 19 : 441–57. [CrossRef] [PubMed] [Google Scholar]
  15. Patel AJ, Willsmore ZN, Khan N, et al. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat Commun 2022; 13 : 3148. [CrossRef] [PubMed] [Google Scholar]
  16. Khan AR, Hams E, Floudas A, et al. PD-L1hi B cells are critical regulators of humoral immunity. Nat Commun 2015 ; 6 : 5997. [CrossRef] [PubMed] [Google Scholar]
  17. Ghosh N, Chan KK, Jivanelli B, et al. Autoantibodies in patients with immune-related adverse events from checkpoint inhibitors: A systematic literature review. J Clin Rheumatol 2022; 28 : e498–505. [CrossRef] [PubMed] [Google Scholar]
  18. Das R, Bar N, Ferreira M, et al. Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 2018 ; 128 : 715–720. [CrossRef] [PubMed] [Google Scholar]
  19. Isnardi I, Ng Y-S, Menard L, et al. Complement receptor 2/CD21– human naive B cells contain mostly autoreactive unresponsive clones. Blood 2010 ; 115 : 11. [Google Scholar]
  20. Fridman WH, Sibéril S, Pupier G, et al. Activation of B cells in tertiary lymphoid structures in cancer: Anti-tumor or anti-self? Semin Immunol 2023; 65 : 101703. [CrossRef] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.